When it comes to brain tumor awareness, I do not think that anyone can argue with the fact that there are many therapies to take into consideration. You want to make sure that these growths are targeted, which is something that cannot be done unless the best procedures are set in place. What can be said about the ICT-107 vaccine, you may wonder? Judging from a recent report, it seems as though this one may be able to prove especially strong when it comes to survival rates amongst patients.
There was a written report on Medical News Today that spoke about this condition, which is something that should be gone about in detail. Glioblastoma multiforme seems to be the name of the game, which isn't hard to see why once you understand the details associated with it. After all, this particular type of brain tumor has been viewed as the most common and aggressive in this field. More details can be picked up on by referring to strong organizations such as Voices against Brain Cancer.
When it comes to the cells that are involved in this particular condition, regeneration seems to come about rather quickly. This is due, at least to some degree, to the blood stream that seems to be rather constant within the body. This is a point that the American Brain Tumor Association went into detail about. In addition, it was said that the risk of the condition increases with age - especially with men - but it seems like it can come about in anyone, regardless of factors like age or gender.
A study that was done by the Cedars-Sinai Medical Group was one that was able to put the ICT-107 vaccine to use. This would be able to benefit the immune system, as it would direct attention to the cancerous cells within the body. After this was done, a tumor-killing response would follow. Keep in mind that this vaccine is administered only after the typical conditions are met, invasive surgery, chemo, and radiation included. After the vaccine was brought into play three times week at two-week intervals, results would be had.
The results were positive, as it seems as though seven of the original sixteen patients were able to see extend survival rates. This would range between 60.7 and 82.7 months, which is quite extensive when considering survival rates for patients. In fact, six of the people involved in the study were said to be "progression-free." This means that not only did these patients have to worry about tumors coming back but they did not have to follow up with further treatment later on, which speaks volumes about the procedure in question.
There was a written report on Medical News Today that spoke about this condition, which is something that should be gone about in detail. Glioblastoma multiforme seems to be the name of the game, which isn't hard to see why once you understand the details associated with it. After all, this particular type of brain tumor has been viewed as the most common and aggressive in this field. More details can be picked up on by referring to strong organizations such as Voices against Brain Cancer.
When it comes to the cells that are involved in this particular condition, regeneration seems to come about rather quickly. This is due, at least to some degree, to the blood stream that seems to be rather constant within the body. This is a point that the American Brain Tumor Association went into detail about. In addition, it was said that the risk of the condition increases with age - especially with men - but it seems like it can come about in anyone, regardless of factors like age or gender.
A study that was done by the Cedars-Sinai Medical Group was one that was able to put the ICT-107 vaccine to use. This would be able to benefit the immune system, as it would direct attention to the cancerous cells within the body. After this was done, a tumor-killing response would follow. Keep in mind that this vaccine is administered only after the typical conditions are met, invasive surgery, chemo, and radiation included. After the vaccine was brought into play three times week at two-week intervals, results would be had.
The results were positive, as it seems as though seven of the original sixteen patients were able to see extend survival rates. This would range between 60.7 and 82.7 months, which is quite extensive when considering survival rates for patients. In fact, six of the people involved in the study were said to be "progression-free." This means that not only did these patients have to worry about tumors coming back but they did not have to follow up with further treatment later on, which speaks volumes about the procedure in question.
About the Author:
Contact Voices Against Brain Cancer if you're looking for some additional information about brain tumor research and awareness.
No comments:
Post a Comment